Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

Ritlecitinib is safe and may effectively treat alopecia areata.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

Ruxolitinib can help regrow hair in severe alopecia areata.